DNA Glycosylases in Noncancer Diseases: Oxidative Lesion Recognition, Repair Intermediates, and Tissue Responses
International Journal of Molecular Sciences · 05.11.2026 · 27 (21) · 9915
DOI: 10.3390/ijms27219915 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.11.2026. Verfasst von Su-Jin Kang und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Dongduk Women's University, Seoul 02748, Republic of Korea. Hauptthemen laut MEDLINE: DNA Glycosylases, Oxidative Stress, DNA Damage, DNA Repair. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT, Korea Basic Science Institute, Ministry of Food and Drug Safety.
Abstract (Originalsprache)
Oxidative DNA damage in noncancer tissues can perturb transcription, compromise telomere integrity, and impair mitochondrial function. DNA glycosylases initiate base excision repair (BER), but their biological consequences also depend on lesion recognition, chromatin residence, catalytic processing, and the persistence or resolution of abasic sites and strand breaks. This review integrates structural and kinetic evidence with experimental models of inflammation, telomeric senescence, cardiometabolic disease, neurodegeneration, and neural injury. Promoter-associated 8-oxoguanine DNA glycosylase 1 (OGG1) can either promote inflammatory transcription or restrict antiviral interferon expression in a locus-dependent manner. At oxidatively damaged telomeres in human fibroblasts, OGG1 and mutY DNA glycosylase (MUTYH) drive acute senescence through repair intermediates, whereas during repeated injury, OGG1 supports telomere maintenance and MUTYH-dependent arrest limits chromosome instability. Mitochondria-directed OGG1 expression improves metabolic outcomes in OGG1-deficient mice exposed to a high-fat diet. By contrast, vascular and neural phenotypes associated with Nei-like DNA glycosylase 3 (NEIL3) remain difficult to attribute to a defined initiating lesion. These findings emphasize distinguishing enzyme occupancy, catalytic processing, and completed repair. Therapeutic studies should define the relevant cell, substrate, compartment, and exposure period and assess tissue function directly alongside unresolved lesions and chromosome stability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Dongduk Women's University, Seoul 02748, Republic of Korea.
- College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
- Graduate Program in Innovative Biomaterial Convergence, Ewha Womans University, Seoul 03760, Republic of Korea.
- College of Pharmacy, Graduate School of Industrial Pharmaceutical Science, Ewha Womans University, Seoul 03760, Republic of Korea.
- Graduate Program in Regulatory Science Convergence, Ewha Womans University, Seoul 03760, Republic of Korea.
ORCID-Profile: Su-Jin Kang, Sunbok Jang
Förderung
- Ministry of Science and ICT
- Korea Basic Science Institute
- Ministry of Food and Drug Safety
- Korean government
- Ministry of Education
Zitieren
APA
Kang, S. J., Ko, Y., Cho, S., & Jang, S. (2026). DNA Glycosylases in Noncancer Diseases: Oxidative Lesion Recognition, Repair Intermediates, and Tissue Responses. International Journal of Molecular Sciences, 27(21), 9915. https://doi.org/10.3390/ijms27219915
Vancouver
Kang SJ, Ko Y, Cho S, Jang S. DNA Glycosylases in Noncancer Diseases: Oxidative Lesion Recognition, Repair Intermediates, and Tissue Responses. International Journal of Molecular Sciences. 2026;27(21):9915. doi:10.3390/ijms27219915
BibTeX
@article{Kang2026,
author = {Kang, Su-Jin and Ko, Yubin and Cho, Subin and Jang, Sunbok},
title = {DNA Glycosylases in Noncancer Diseases: Oxidative Lesion Recognition, Repair Intermediates, and Tissue Responses},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9915},
doi = {10.3390/ijms27219915}
}
EUVIMED